Read more

December 15, 2022
1 min read
Save

Top in hem/onc: Cumulative stress and cancer risk; thromboembolism biomarkers in COVID-19

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

High allostatic load indicating lifelong stress was linked to a 106% increased risk for cancer-associated death among young Black individuals and a 95% increased risk among young white individuals, according to a recent study.

Based on the findings, researchers and clinicians should consider novel approaches using multilevel strategies that reduce chronic stress and inflammation, study coauthor Justin Xavier Moore, PhD, said. It was the top story in hematology/oncology last week.

Image of burnout
Patients with cancer and COVID-19 exhibited a 3% risk for thromboembolism within 30 days of their first positive test, data show. Source: Adobe Stock

Another top story was about a presentation at the ASH Annual Meeting and Exposition on hemostatic biomarkers that appeared to predict the risk for thromboembolism and mortality in patients with cancer and COVID-19.

Read these and more top stories in hematology/oncology below:

Lifelong stress may increase risk for cancer mortality

Higher allostatic load, a measure of lifelong stress, correlated with increased risk for cancer mortality, especially among younger populations, according to study results published in SSM Population Health. Read more.

Biomarkers predict thromboembolism risk, mortality among people with cancer, COVID-19

Patients with cancer and COVID-19 exhibited a 3% risk for thromboembolism within 30 days of their first positive test, according to study results presented at ASH Annual Meeting and Exposition. Watch here.

Pausing endocrine therapy for pregnancy appears safe for women with breast cancer

Young women with early hormone receptor-positive breast cancer who temporarily stopped endocrine therapy to attempt pregnancy experienced similar short-term recurrence risk as those who did not stop, according to study results. Read more.

Trastuzumab deruxtecan ‘new gold standard’ in second line for breast cancer subset

Fam-trastuzumab deruxtecan-nxki significantly extended overall survival compared with ado-trastuzumab emtansine among previously treated patients with HER2-positive unresectable or metastatic breast cancer, according to study results. Read more.

Patient navigation reduces costs of care for patients with cancer in statewide health plan

Patient navigation programs have historically been difficult to implement on a large scale. To help address this challenge, researchers investigated a scalable, independent program in collaboration with a large, statewide Medicare Advantage plan in New Jersey. Read more.